Novo Net Debt vs Current Deferred Revenue Analysis

NVO Stock

USD 124.02 5.19 4.02%

Novo Nordisk financial indicator trend analysis is infinitely more than just investigating Novo Nordisk AS recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novo Nordisk AS is a good investment. Please check the relationship between Novo Nordisk Net Debt and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novo Nordisk AS Net Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Novo Nordisk's Net Debt and Current Deferred Revenue is 0.77. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Novo Nordisk AS, assuming nothing else is changed. The correlation between historical values of Novo Nordisk's Net Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Novo Nordisk AS are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Debt i.e., Novo Nordisk's Net Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Novo Nordisk's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Novo Nordisk's Selling General Administrative is very stable compared to the past year. As of the 2nd of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.04, while Tax Provision is likely to drop about 12.8 B.

	2021	2022	2023	2024 (projected)
Gross Profit	117.1B	148.5B	196.5B	206.3B
Total Revenue	140.8B	177.0B	232.3B	243.9B

Gross Profit Total Revenue

Novo Nordisk fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Other Current Assets	Accounts Payable	Common Stock Total Equity	Common Stock
Total Assets		0.92	0.56	1.0	0.98	0.99	0.78	0.98	0.0	1.0	-0.15	0.84	1.0	0.45	0.96	0.98	-0.27	1.0	0.99	0.99	0.62	0.96	0.47	0.96	-0.68	-0.69
Short Long Term Debt Total	0.92		0.59	0.92	0.87	0.88	0.95	0.86	-0.24	0.95	-0.32	0.64	0.92	0.36	0.97	0.85	-0.21	0.94	0.96	0.88	0.76	0.98	0.49	0.85	-0.52	-0.53
Other Current Liab	0.56	0.59		0.54	0.53	0.53	0.55	0.52	-0.03	0.57	-0.08	0.39	0.56	0.3	0.65	0.53	-0.16	0.57	0.59	0.54	0.11	0.59	0.39	0.49	-0.41	-0.45
Total Current Liabilities	1.0	0.92	0.54		0.97	0.98	0.78	0.97	-0.02	1.0	-0.13	0.82	1.0	0.46	0.96	0.98	-0.29	1.0	0.98	0.99	0.63	0.96	0.44	0.97	-0.66	-0.66
Total Stockholder Equity	0.98	0.87	0.53	0.97		0.98	0.69	1.0	0.12	0.97	-0.12	0.87	0.98	0.47	0.92	0.99	-0.28	0.97	0.95	0.99	0.6	0.91	0.5	0.94	-0.78	-0.78
Property Plant And Equipment Net	0.99	0.88	0.53	0.98	0.98		0.72	0.98	0.05	0.98	-0.09	0.8	0.98	0.54	0.92	0.99	-0.29	0.98	0.95	0.98	0.61	0.93	0.43	0.94	-0.73	-0.73
Net Debt	0.78	0.95	0.55	0.78	0.69	0.72		0.68	-0.51	0.83	-0.47	0.4	0.78	0.18	0.88	0.66	-0.15	0.81	0.85	0.7	0.73	0.91	0.44	0.72	-0.26	-0.27
Retained Earnings	0.98	0.86	0.52	0.97	1.0	0.98	0.68		0.14	0.96	-0.1	0.87	0.98	0.49	0.9	0.99	-0.28	0.96	0.94	0.99	0.61	0.91	0.48	0.93	-0.8	-0.8
Cash	0.0	-0.24	-0.03	-0.02	0.12	0.05	-0.51	0.14		-0.07	0.54	0.35	0.01	0.47	-0.16	0.15	-0.1	-0.05	-0.1	0.1	-0.18	-0.21	0.03	-0.06	-0.63	-0.6
Non Current Assets Total	1.0	0.95	0.57	1.0	0.97	0.98	0.83	0.96	-0.07		-0.19	0.79	0.99	0.44	0.97	0.97	-0.26	1.0	0.99	0.98	0.65	0.98	0.47	0.96	-0.64	-0.65
Non Currrent Assets Other	-0.15	-0.32	-0.08	-0.13	-0.12	-0.09	-0.47	-0.1	0.54	-0.19		0.01	-0.13	0.56	-0.27	-0.03	-0.16	-0.16	-0.17	-0.09	-0.25	-0.27	-0.15	-0.14	-0.15	-0.15
Cash And Short Term Investments	0.84	0.64	0.39	0.82	0.87	0.8	0.4	0.87	0.35	0.79	0.01		0.84	0.31	0.76	0.86	-0.13	0.81	0.8	0.89	0.31	0.72	0.34	0.86	-0.71	-0.71
Net Receivables	1.0	0.92	0.56	1.0	0.98	0.98	0.78	0.98	0.01	0.99	-0.13	0.84		0.46	0.96	0.98	-0.29	1.0	0.99	0.99	0.62	0.96	0.46	0.97	-0.68	-0.69
Common Stock Shares Outstanding	0.45	0.36	0.3	0.46	0.47	0.54	0.18	0.49	0.47	0.44	0.56	0.31	0.46		0.36	0.55	-0.32	0.44	0.41	0.46	0.37	0.36	0.23	0.31	-0.66	-0.66
Non Current Liabilities Total	0.96	0.97	0.65	0.96	0.92	0.92	0.88	0.9	-0.16	0.97	-0.27	0.76	0.96	0.36		0.9	-0.17	0.97	0.98	0.94	0.6	0.99	0.48	0.93	-0.54	-0.55
Inventory	0.98	0.85	0.53	0.98	0.99	0.99	0.66	0.99	0.15	0.97	-0.03	0.86	0.98	0.55	0.9		-0.3	0.97	0.94	0.99	0.58	0.9	0.44	0.94	-0.78	-0.78
Other Stockholder Equity	-0.27	-0.21	-0.16	-0.29	-0.28	-0.29	-0.15	-0.28	-0.1	-0.26	-0.16	-0.13	-0.29	-0.32	-0.17	-0.3		-0.26	-0.24	-0.28	-0.21	-0.22	-0.39	-0.23	0.36	0.36
Total Liab	1.0	0.94	0.57	1.0	0.97	0.98	0.81	0.96	-0.05	1.0	-0.16	0.81	1.0	0.44	0.97	0.97	-0.26		0.99	0.98	0.62	0.98	0.45	0.97	-0.64	-0.64
Property Plant And Equipment Gross	0.99	0.96	0.59	0.98	0.95	0.95	0.85	0.94	-0.1	0.99	-0.17	0.8	0.99	0.41	0.98	0.94	-0.24	0.99		0.97	0.66	0.99	0.49	0.95	-0.61	-0.62
Total Current Assets	0.99	0.88	0.54	0.99	0.99	0.98	0.7	0.99	0.1	0.98	-0.09	0.89	0.99	0.46	0.94	0.99	-0.28	0.98	0.97		0.57	0.93	0.46	0.96	-0.73	-0.73
Short Term Debt	0.62	0.76	0.11	0.63	0.6	0.61	0.73	0.61	-0.18	0.65	-0.25	0.31	0.62	0.37	0.6	0.58	-0.21	0.62	0.66	0.57		0.69	0.37	0.47	-0.47	-0.48
Intangible Assets	0.96	0.98	0.59	0.96	0.91	0.93	0.91	0.91	-0.21	0.98	-0.27	0.72	0.96	0.36	0.99	0.9	-0.22	0.98	0.99	0.93	0.69		0.49	0.92	-0.54	-0.54
Other Current Assets	0.47	0.49	0.39	0.44	0.5	0.43	0.44	0.48	0.03	0.47	-0.15	0.34	0.46	0.23	0.48	0.44	-0.39	0.45	0.49	0.46	0.37	0.49		0.4	-0.47	-0.47
Accounts Payable	0.96	0.85	0.49	0.97	0.94	0.94	0.72	0.93	-0.06	0.96	-0.14	0.86	0.97	0.31	0.93	0.94	-0.23	0.97	0.95	0.96	0.47	0.92	0.4		-0.56	-0.55
Common Stock Total Equity	-0.68	-0.52	-0.41	-0.66	-0.78	-0.73	-0.26	-0.8	-0.63	-0.64	-0.15	-0.71	-0.68	-0.66	-0.54	-0.78	0.36	-0.64	-0.61	-0.73	-0.47	-0.54	-0.47	-0.56		0.99
Common Stock	-0.69	-0.53	-0.45	-0.66	-0.78	-0.73	-0.27	-0.8	-0.6	-0.65	-0.15	-0.71	-0.69	-0.66	-0.55	-0.78	0.36	-0.64	-0.62	-0.73	-0.48	-0.54	-0.47	-0.55	0.99

Click cells to compare fundamentals

Novo Nordisk Account Relationship Matchups

Novo Nordisk fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	125.6B	144.9B	194.5B	241.3B	314.5B	330.2B
Short Long Term Debt Total	4.5B	10.4B	26.6B	25.8B	27.0B	28.4B
Other Current Liab	15.8B	18.4B	21.8B	103.9B	30.0B	31.5B
Total Current Liabilities	59.0B	70.3B	99.5B	120.9B	169.7B	178.1B
Total Stockholder Equity	57.6B	63.3B	70.7B	83.5B	106.6B	111.9B
Property Plant And Equipment Net	50.6B	50.3B	55.4B	66.7B	91.0B	95.5B
Net Debt	(11.0B)	(2.4B)	15.9B	13.1B	12.6B	13.2B
Retained Earnings	57.8B	63.8B	72.0B	80.6B	104.8B	110.1B
Cash	15.5B	12.8B	10.7B	12.7B	14.4B	8.1B
Non Current Assets Total	63.2B	79.1B	108.9B	133.1B	174.8B	183.6B
Non Currrent Assets Other	841M	674M	267M	206M	1.4B	1.4B
Cash And Short Term Investments	15.5B	12.8B	17.5B	23.6B	30.2B	31.7B
Net Receivables	29.2B	32.2B	46.8B	57.5B	75.3B	79.0B
Common Stock Shares Outstanding	4.8B	4.7B	4.6B	4.5B	4.5B	3.7B
Liabilities And Stockholders Equity	125.6B	144.9B	194.5B	241.3B	314.5B	330.2B
Non Current Liabilities Total	9.0B	11.3B	24.2B	36.8B	38.3B	40.2B
Inventory	17.6B	18.5B	19.6B	24.4B	31.8B	33.4B
Total Liab	68.0B	81.6B	123.8B	157.8B	207.9B	218.3B
Property Plant And Equipment Gross	30.3B	50.3B	95.9B	111.4B	138.6B	145.5B
Total Current Assets	62.5B	65.8B	85.6B	108.2B	139.6B	146.6B
Accumulated Other Comprehensive Income	(694M)	(911M)	(1.7B)	2.4B	1.3B	1.3B
Short Term Debt	1.5B	7.5B	13.7B	1.5B	6.5B	6.8B
Intangible Assets	5.8B	20.7B	38.8B	46.3B	55.9B	58.7B
Other Current Assets	188M	2.3B	1.7B	2.7B	2.3B	1.5B
Accounts Payable	6.4B	5.7B	8.9B	15.6B	25.6B	26.9B
Common Stock Total Equity	500M	490M	480M	470M	423M	493.1M
Common Stock	480M	470M	462M	456M	451M	478.4M
Other Liab	6.0B	8.4B	11.3B	12.5B	14.4B	15.1B
Property Plant Equipment	50.6B	50.3B	55.4B	66.7B	76.7B	80.5B
Current Deferred Revenue	35.3B	38.7B	55.2B	107.6B	123.7B	129.9B
Other Assets	5.0B	6.5B	8.9B	13.4B	15.4B	16.2B
Net Tangible Assets	51.8B	42.7B	27.6B	32.1B	36.9B	37.0B
Long Term Investments	1.8B	1.6B	1.4B	1.3B	1.7B	1.5B
Short Long Term Debt	659M	6.7B	12.9B	480M	5.3B	2.9B
Long Term Debt Total	3.0B	2.9B	13.0B	24.3B	28.0B	29.4B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:

How To Invest In Novo

Details

Is Novo Stock a good investment?

Details

What is Novo Nordisk's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Novo Stock analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.

	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.631

Dividend Share

9.4

Earnings Share

2.67

Revenue Per Share

51.812

Quarterly Revenue Growth

0.37

The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novo Net Debt vs Current Deferred Revenue Analysis

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Debt

Current Deferred Revenue

Novo Nordisk fundamental ratios Correlations

Novo Nordisk Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novo Nordisk fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novo Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Total Current Liabilities

Common Stock	- 0.8	Retained Earnings
Common Stock Total Equity	- 0.8	Retained Earnings
Common Stock	- 0.78	Inventory
Common Stock Total Equity	- 0.78	Inventory
Common Stock	- 0.78	Total Stockholder Equity
Common Stock Total Equity	- 0.78	Total Stockholder Equity